The data presented shows that tilvestamab prevents AXL mediated cell signaling in cancer cell lines, reduces cell migration and invasion and shows anti-tumor efficacy in a panel of mouse xenograft models. Further it is shown that in a non-human primate dose-ranging toxicokinetic study, tilvestamab was well tolerated during dosing phase up to the highest studied dose of 25mg/kg. Tilvestamab is currently being evaluated in a Phase I clinical study (BGB149-101; NCT03795142) in healthy volunteers to evaluate safety, tolerability and pharmacokinetics.
The meeting will run from
Title: Tilvestamab, a novel clinical stage humanized anti-AXL function blocking antibody
Date:
Link to Abstract (https://cm.eortc.org/cmPortal/Searchable/ENA2020/config/normal#!abstractdetails/0000897260)
- END -
About AXL
AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms underlying many life-threatening diseases. In cancer, AXL suppresses the body's immune response to tumours and drives cancer treatment failure across many indications. AXL expression defines a very poor prognosis subgroup in most cancers. AXL inhibitors, therefore, have potential high value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities. Research has also shown that AXL mediates other aggressive diseases.
About Bemcentinib
Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme. Ongoing clinical trials are investigating bemcentinib in multiple solid and haematological tumours, in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy), and as a single agent. Bemcentinib targets and binds to the intracellular catalytic kinase domain of AXL receptor tyrosine kinase and inhibits its activity. Increase in AXL function has been linked to key mechanisms of drug resistance and immune escape by tumour cells, leading to aggressive metastatic cancers.
About
Contacts
+47 917 86 304
rune.skeie@bergenbio.com
+47 917 86 513
International Media Relations
bergenbio@consilium-comms.com
+44 20 3709 5700
Media Relations in
stiff@crux.no
+47 995 13 891
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
https://news.cision.com/bergenbio-asa/r/bergenbio-presents-data-on-anti-axl-antibody-tilvestamab-at-32-nd--ena-symposium,c3212845
https://mb.cision.com/Main/15728/3212845/1318544.pdf
(c) 2020 Cision. All rights reserved., source